Statement by Dr Alan Howard, National Medical Director, KetaMIND : SASOP has issued three position statements since 2022 outlining their stance on a current hot topic; administration of low dose ketamine infusion for Treatment Resistant Depression (TRD)
Bedfordview (GP)
Bryanston (GP)
Hillcrest (KZN)
PMB (KZN)
Umhlanga (KZN)
Constantia (WC)
Paarl (WC)
Archives: Literature Documents
Literature Document
Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression
Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression.
Literature Document
Case report: Adult with bipolar disorder and autism treated with ketamine
Clinical evidence of an association between Bipolar Disorder (BD) and Autism Spectrum Disorder (ASD) is well documented (1–4) with both conditions possibly sharing the same genes. Comorbid conditions with ASD, including BD, can negatively impact quality of life and significantly increase difficulties in adaptive responses and daily activities…
Literature Document
Ketamine and the Complement System
Over 300 million people worldwide suffer from major depressive disorder (MDD). Unfortunately, only 30–40% of patients with MDD achieve complete remission after conventional monoamine antidepressant therapy. In recent years, ketamine has revolutionized the treatment of MDD, with its rapid antidepressant effects manifesting within a few hours as opposed to weeks with conventional antidepressants.
Literature Document
Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population.
Literature Document
Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans
Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking. Herein, we aim to inform prediction models of non-response to ketamine/esketamine in adults with TRD.
Literature Document
Is Polycystic Ovary Syndrome (PCOS) a Risk Factor for Suicidal Ideation?
Polycystic ovary syndrome (PCOS) affects a significant proportion of women during their reproductive years and is characterized by elevated androgen levels that are often associated with insulin resistance.
Literature Document
Ketamine for depressive symptoms: A retrospective chart review of a private ketamine clinic
This retrospective chart review reports the clinical response (change in Patient Health Questionnaire – 7 score) to an initial infusion series of ketamine added to usual treatment, and the pattern of its subsequent maintenance use, for depressive symptoms.
Literature Document
Unexpected ketamine effect in a patient with cervical dystonia
Cervical dystonia is the most common form of adult-onset focal dystonia. It is a highly disabling disorder that negatively impacts quality of life.
Literature Document
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
NMDA receptor antagonists have a vital role in extinction, learning, and reconsolidation processes. During the reconsolidation window, memories are activated into a labile state and can be reconsolidated in an altered form. This concept might have significant clinical implications in treating PTSD.